We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -74.00 | -0.60% | 12,172.00 | 12,166.00 | 12,170.00 | 12,306.00 | 12,132.00 | 12,240.00 | 1,412,854 | 16:35:18 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.68 | 188.63B |
From May 2019 to May 2024
By Ian Walker
LONDON--Pharmaceutical giant AstraZeneca PLC (AZN.LN) said Tuesday the U.S. Food and Drug Administration has approved once-daily Qtern for the treatment of type-2 diabetes.
The new medicine is indicated as an addition to diet and exercise to improve blood sugar level control in adults with type-2 diabetes who have inadequate control with dapagliflozin, or who are already treated with dapagliflozin and saxagliptin, Astra said.
-Write to Ian Walker at ian.walker@wsj.com; @IanWalk40289749
(END) Dow Jones Newswires
February 28, 2017 02:34 ET (07:34 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
